Share
Tumor Immunology and Immunotherapy Resistance
Subramanian, Subree ; Starr, Timothy K. ; Zhao, Xianda (Author)
·
Mdpi AG
· Hardcover
Tumor Immunology and Immunotherapy Resistance - Subramanian, Subree ; Starr, Timothy K. ; Zhao, Xianda
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My Wishlists
Origin: U.S.A.
(Import costs included in the price)
It will be shipped from our warehouse between
Monday, August 12 and
Monday, August 19.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "Tumor Immunology and Immunotherapy Resistance"
In recent years, cancer immunotherapy has made remarkable progress, revolutionizing cancer treatment. Our Special Issue "Cancer Immunology" in the journal Cancers showcased cutting-edge research and reviews. Building on that success, this new Special Issue explores recent advancements, technologies, and future prospects in cancer immunology, pre-clinical assessments, and clinical trials. While immune checkpoint inhibitors have been transformative, addressing limited response remains crucial. Strategies to overcome resistance, such as combination therapies and targeted pathways, are discussed in the issue. Chimeric antigen receptor (CAR) T cell therapy is an important area of immunotherapy, with exciting findings for enhancing CAR persistence and efficacy. Conventional treatments and monoclonal antibodies also activate immunological mechanisms, boosting cytotoxic efficacy against specific cancers. Identifying biomarkers associated with treatment response is vital for personalized cancer immunotherapy. Potential biomarkers like immune cell densities and estrogen receptor expression are explored in this Issue. The review articles cover advancements in CAR T cell therapy, tumor metabolic alterations, immune suppressive cells, and the role of bacteria in cancer immunotherapy. This Special Issue is a valuable resource for researchers, clinicians, and industry professionals, guiding future developments towards more effective and personalized cancer immunotherapies.
